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WNT signaling controls many biological processes
including cell differentiation in metazoans. However,
how WNT reprograms cell identity is not well under-
stood. We have investigated the potential role of
cellular metabolism in WNT-induced osteoblast
differentiation. WNT3A induces aerobic glycolysis
known as Warburg effect by increasing the level of
key glycolytic enzymes. The metabolic regulation re-
quires LRP5 but not b-catenin and is mediated
by mTORC2-AKT signaling downstream of RAC1.
Suppressing WNT3A-induced metabolic enzymes
impairs osteoblast differentiation in vitro. Deletion
of Lrp5 in the mouse, which decreases postnatal
bone mass, reduces mTORC2 activity and glycolytic
enzymes in bone cells and lowers serum lactate
levels. Conversely, mice expressing a mutant Lrp5
that causes high bonemass exhibit increased glycol-
ysis in bone. Thus, WNT-LRP5 signaling promotes
bone formation in part through direct reprogramming
of glucose metabolism. Moreover, regulation of
cellular metabolism may represent a general mecha-
nism contributing to the wide-ranging functions of
WNT proteins.
INTRODUCTION
WNT signaling controls cell proliferation, fate decision, polarity,
and migration throughout the evolution of metazoans (Croce
and McClay, 2008). WNT proteins, by engaging various recep-
tors and coreceptors at the cell membrane, activate an intracel-
lular signaling network highly dependent on the cellular context,
to induce diverse biological responses (van Amerongen and
Nusse, 2009). WNT signaling through b-catenin has been most
extensively studied. In this mechanism, binding of WNT to a Friz-
zled (Fz) receptor and a LRP5/6 coreceptor leads to stabilization
of b-catenin, which subsequently translocates to the nucleus,
where it interacts with members of the TCF/LEF transcription
factors to activate transcription of downstream target genesC(Clevers, 2006). In addition, WNT proteins can activate the Rho
family of small GTPases (Habas et al., 2001, 2003; Wu et al.,
2008), the Ca2+ pathway (Ku¨hl et al., 2000), and PKCd (Kinoshita
et al., 2003; Tu et al., 2007).WNT has also been shown to activate
mTORC1 (mammalian target of rapamycin complex 1), one of the
two complexes formed by mTOR (Inoki et al., 2006). Whereas
mTORC1 uniquely contains raptor and is the main target of rapa-
mycin, mTORC2 contains rictor and is relatively insensitive to the
drug (Laplante and Sabatini, 2012; Wullschleger et al., 2006).
Among many other functions, mTORC1 is best known to control
protein synthesis through phosphorylation of the translational
regulators 4E-BP1 and S6K1, the latter of which in turn phos-
phorylates the ribosomal protein S6 and other substrates (Ma
and Blenis, 2009). mTORC2 is known to activate Akt through
phosphorylation at Ser473, which is necessary for its activity
toward some but not all substrates (Guertin et al., 2006; Hresko
andMueckler, 2005; Jacinto et al., 2006; Sarbassov et al., 2005).
Other targets of mTORC2 include PKCa, FOXO3, and SGK1
(Garcı´a-Martı´nez and Alessi, 2008; Guertin et al., 2006). Earlier
studies with siRNA have implicated mTORC2 signaling in regu-
lating the actin cytoskeleton (Jacinto et al., 2004; Sarbassov
et al., 2004), but this function was not confirmed in embryonic
fibroblasts derived from knockout mice (Guertin et al., 2006).
On the other hand, mTORC2 has been shown to regulate
whole-body glucose and lipid metabolism through its action in
the liver and the adipose tissue (Cybulski et al., 2009; Hagiwara
et al., 2012; Kumar et al., 2010; Lamming et al., 2012). Recent
studies have shown that the small GTPase RAC1 localizes
mTOR to specific membranes and mediates the activation of
both mTORC1 and mTORC2 in response to growth factors
(Saci et al., 2011). In addition, ribosomes activate mTORC2
through physical association (Zinzalla et al., 2011). Whether or
not WNT signaling activates mTORC2 has not been explored.
WNT signaling has emerged as an important mechanism regu-
lating bone formation in mammals (Long, 2012). In the mouse
embryo, deletion of b-catenin, or both LRP5 and LRP6, in the
skeletogenic progenitors abolishes osteoblast differentiation,
indicating that WNT signaling through b-catenin is critical for
embryonic osteoblastogenesis (Day et al., 2005; Hill et al.,
2005; Hu et al., 2005; Joeng et al., 2011; Rodda and McMahon,
2006). Postnatally, loss- and gain-of-function mutations in LRP5
cause low and high bone mass syndromes, respectively, in
humans (Boyden et al., 2002; Gong et al., 2001; Little et al.,ell Metabolism 17, 745–755, May 7, 2013 ª2013 Elsevier Inc. 745
Figure 1. WNT Stimulates Glucose Con-
sumption in Cell Culture
(A) Increase in glucose consumption by ST2 cells
treated with WNT3A (W) over vehicle (V) for indi-
cated times.
(B) Glucose uptake assay following WNT3A (W) or
vehicle (V) treatment for indicated times.
(C) Induced glucose consumption after 24 hr by
purified WNT3A (3A) or virally expressed WNT10B
(10B). Increases as percent over control cells
incubated with vehicle (V) and a GFP-producing
virus (IE).
(D–G) Induced glucose consumption by WNT3A
in indicated cell lines, MEFs, and mouse calvarial
cells. Increases as percent over vehicle-treated
cells. Asterisk denotes significant difference
over respective controls, n = 3, p < 0.05. Error
bars, SD.
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WNT-LRP5-mTORC2 Signaling Induces Glycolysis2002). Moreover, deficiency in SOST, a secreted inhibitor that
prevents the binding of WNT to LRP5 or LRP6, results in high
bone mass in human patients (Balemans et al., 2001, 2002). In
the mouse, deletion of LRP5 causes osteopenia (Cui et al.,
2011; Kato et al., 2002), whereas loss of SOST increases bone
mass (Li et al., 2008). The mechanism through which WNT
signaling stimulates osteoblast differentiation, however, remains
to be elucidated.
Emerging evidence has implicated WNT signaling in the regu-
lation of cellular metabolism. A missense mutation in LRP6 has
been linked with abnormal whole-body metabolism in humans
(Mani et al., 2007). Genomic polymorphism of TCF7L2, a tran-
scriptional effector of WNT/b-catenin signaling, is associated
with type II diabetes (Grant et al., 2006). In cell culture models,
prolonged WNT treatment induced mitochondria biogenesis in
a b-catenin-dependent manner (Yoon et al., 2010). In the mouse,
hepatic manipulation of b-catenin was shown to regulate
glucose and glutamine metabolism (Cadoret et al., 2002; Chafey
et al., 2009; Liu et al., 2011). However, whether WNT regulates
cellular metabolism via b-catenin-independent mechanisms
has not been examined. Moreover, it is not knownwhethermeta-
bolic regulation by WNT contributes to cell differentiation.
Here we investigate the potential regulation of glucose meta-
bolism by WNT during osteoblast differentiation. We report
that multiple WNT proteins acutely stimulate aerobic glycolysis
to control osteoblast differentiation. Distinct from the previous
findings, the metabolic regulation described here is independent
of b-catenin signaling but requires mTORC2 activation. Impor-
tantly, mouse genetic models demonstrate that WNT-LRP5
signaling concurrently increases glycolysis and bone formation
in vivo. Thus, WNT signaling reprograms glucose metabolism
through a direct mechanism, and WNT-induced metabolic re-
programming contributes to osteoblast differentiation.
RESULTS
WNT Induces Aerobic Glycolysis Independent
of b-Catenin
To investigate a potential link between WNT signaling, cellular
metabolism, and osteoblast differentiation, we examined the746 Cell Metabolism 17, 745–755, May 7, 2013 ª2013 Elsevier Inc.effect of WNT proteins on glucose metabolism in ST2 cells, a
mouse bone marrow stromal cell line known to undergo osteo-
blast differentiation in response to WNT (Tu et al., 2007).
Because we were interested in direct regulation by WNT instead
of adaptive effects secondary to the differentiated state, we
focused on the response within the first 24 hr of treatment. Puri-
fied WNT3A progressively increased glucose consumption over
the control, reaching statistical significance at 6 hr and exhibiting
a marked increase at 12 and 24 hr (Figure 1A). Importantly, dur-
ing this time period, WNT3A did not increase the number of cells
or alter the cell-cycle distribution (see Figures S1A and S1B on-
line). Compared to WNT3A, insulin at high concentrations (1 or
2 mg/ml) was less effective in stimulating glucose consumption
in ST2 cells (Figure S1C). Moreover, WNT3A stimulated glucose
consumption in the absence of serum even though overall
glucose consumption was lower at both basal and stimulated
conditions (Figure S1D). Consistent with the increased glucose
consumption, glucose uptake, as assayed by fluorescently
labeled 2-deoxyglucose, was enhanced following 1, 12, or
24 hr of WNT3A treatment (Figure 1B). Thus, WNT3A acutely
induces glucose consumption in ST2 cells.
We then examined whether the regulation was limited to
WNT3A and undifferentiated ST2 cells. WNT10B has been
shown to induce osteoblast differentiation in ST2 cells (Kang
et al., 2007). We found that virally expressed WNT10B increased
glucose consumption to an extent comparable to that of purified
WNT3A (Figure 1C). In contrast, recombinant WNT5A did not
have a similar effect (Figure S1E). BMP2, a known inducer of
osteoblast differentiation in ST2 cells, did not stimulate glucose
consumption after 24 hr of treatment (Figure S1F). To determine
the effect of WNT3A on differentiating ST2 cells, we stimulated
them with an established osteogenic media containing dexa-
methasone, b-glycerophosphate, and ascorbate for up to
15 days and then assessed their response to WNT3A for 24 hr
at each differentiation stage. WNT3A stimulated glucose con-
sumption in ST2 cells at all stages (Figures S1G and S1H). We
then tested the effect of WNT3A on other cell lines as well as pri-
mary cell cultures. We found that WNT3A stimulated glucose
consumption in C2C12 (myoblast), M2-10B4 (bone marrow stro-
mal cell), MC3T3 (preosteoblast), MLO-Y4 cells (osteocyte), and
Figure 2. WNT3A Stimulates Aerobic
Glycolysis in ST2 Cells
(A) Media lactate levels following vehicle (V) or
WNT3A (W) treatments.
(B) Media lactate levels following viral expression
of GFP (IE) or WNT10B for 24 hr.
(C and D) Extracellular acidification rate (ECAR)
(C) and oxygen consumption rate (OCR) (D) after
6 hr of WNT3A (W) or vehicle (V) treatment.
(E) Measurements of ECAR and OCR after 24 hr of
treatment.
(F) Intracellular ATP levels after 24 hr of treatment.
(G–I) Isotopomer enrichment of [U-13C3]-lactate
and [U-13C6]-glucose in cell lysates after 6 (G),
12 (H), or 24 (I) hr of WNT3A (W) or vehicle (V)
treatment. Asterisk, n = 3, p < 0.05. Error bars, SD.
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mouse embryonic fibroblasts (MEFs) and osteoblast-lineage
cells from the mouse calvaria (Figures 1D–1G). Thus, multiple
osteogenic WNT ligands increase glucose consumption, but all
osteogenic signals do not exhibit the same regulation. Further-
more, WNT3A stimulates glucose consumption in a variety of
cell types.
We next examined potential metabolic changes in ST2 cells.
WNT3A markedly increased the concentration of lactate in the
culture media at both 6 and 24 hr of treatment (Figure 2A). Simi-
larly, WNT10B increased lactate levels at 24 hr (Figure 2B).
WNT5A, on the other hand, did not affect lactate levels (Fig-
ure S1I), even though it induced phosphorylation of MARC.KS
in ST2 cells (Figure S1J). We next measured extracellular acidifi-
cation rate (ECAR) as an indicator for lactate production rate, and
the oxygen consumption rate (OCR) with the Extracellular Flux
Analyzer after 6 hr ofWNT stimulation.WNT3A notably increased
ECAR both at the basal state and during mitochondria stress
tests with oligomycin or FCCP, but had no effect on the OCR
under all conditions (Figures 2C and 2D). Similarly, after 24 hr,
WNT3A increased ECAR but not OCR (Figure 2E). Moreover,
WNT3A did not alter the intracellular ATP levels after 24 hr of
treatment (Figure 2F). Thus, WNT signaling stimulated lactate
production but not oxidative phosphorylation.
To demonstrate that WNT3A stimulates lactate production
directly from glucose, we tracked the fate of glucose through iso-
topomer distribution analyses of stable isotopically labeled sub-
strates through GC/MS. Briefly, cells were first stimulated with
WNT3A for 6, 12, or 24 hr and then incubated with 13C-labeled
glucose ([U-13C6]-glucose, m+6 isotopomer tracer) for 1 hr,
and its contribution to lactate through glycolysis was determined
by measuring the abundance of the labeled [U-13C3]-lactate
(m+3 isotopomer) relative to the unlabeled (m+0) pool. After 6,
12, or 24 hr of stimulation, WNT3A markedly increased theCell Metabolism 17, 745relative abundance of m+3 lactate in the
cell lysate, indicating a greater portion
of lactate derived through glycolysis
(Figures 2G–2I). Moreover, at all time
points, the WNT3A-induced enrichment
of labeled lactate was greater than
that of the intracellular labeled glucose
(m+6/m+0), indicating that a greaterportion of the intracellular glucose underwent glycolysis in
response to WNT3A (Figures 2G–2I). Thus, WNT signaling
stimulates glycolysis despite the abundance of oxygen, a
phenomenon known as the Warburg effect.
We next examined the molecular basis for the increased
glycolysis. GLUT1, a main glucose transporter, and hexokinase
II (HK2) that catalyzes the first rate-limiting step of glucose
catabolism were both induced by WNT3A at 1 hr and remained
high at 6, 12, and 24 hr of treatment (Figure 3A and data not
shown). Phosphofructokinase 1 (PFK1), a key regulatory enzyme
for the ‘‘committed step’’ of glycolysis, and 6-phosphofructo-2-
kinase/fructose-2, 6-bisphosphatase 3 (PFKFB3), which con-
trols the concentration of fructose 2,6-bisphosphate, a potent
allosteric activator of PFK1, were both induced by WNT3A,
although PFKFB3 returned to control levels by 24 hr of treatment
(Figure 3A). Finally, lactate dehydrogenase A (LDHA), which
catalyzes the conversion of pyruvate to lactate, and pyruvate
dehydrogenase kinase 1 (PDK1) that inactivates the pyruvate
dehydrogenase complex to suppress pyruvate from entering
the TCA cycle were both induced by 6 hr of WNT3A stimulation
and remained high at the later time points (Figure 3A). Quantifica-
tion of western blots from multiple independent experiments
confirmed that the glycolytic regulators were consistently
induced by WNT3A after 1, 6, and 24 hr of treatment (Figures
S2A–S2C). Interestingly, when ST2 cells were first starved for
serum, WNT3A induced not only HK2 but also LDHA and
PDK1 after 1 hr of stimulation (Figure 3B). Further experiments
revealed that these enzymes were in fact upregulated by
WNT3A within 5 min of stimulation in the serum-starved cells
(Figure S2D). The quick induction of the enzymes is not likely
to be due to transcriptional regulation, as their mRNA levels
stayed relatively unchanged even after 6 hr of WNT3A treatment
(Figure S2E). After 24 hr, only Ldha and Pdk1 mRNA but not the
others were increased over the control (Figure S2F). Knockdown–755, May 7, 2013 ª2013 Elsevier Inc. 747
Figure 3. WNT3A Induces Glycolysis Inde-
pendent of GSK3b and b-Catenin
(A and B) Representative western blots of glyco-
lytic regulators in ST2 cells treated with WNT3A or
vehicle in the presence (A) or absence of serum
(B) for indicated times. Cells in (B) starved for
serum for 12 hr before treatment. Protein abun-
dance normalized to b-actin.
(C) Knockdown of LDHA or PDK1. shGfp as
negative control. Protein abundance normalized
to a-tubulin.
(D) Effect of LDHA or PDK1 knockdown on
WNT3A-induced glucose consumption.
(E) Effect of GSK3b knockdown on WNT3A-
induced glucose consumption. Increase in
glucose consumption as percent over cells treated
with shGfp and vehicle.
(F) Effect of GSK3b knockdown on b-catenin.
(G) Knockdown of b-catenin and its effect on IRS1.
(H) Effect of b-catenin knockdown on WNT3A-
induced glucose consumption.
(I and J) Effect of XAV-939 on b-catenin (I) and
WNT3A-induced glucose consumption (J). All glu-
cose consumptionmeasured after 24 hr ofWNT3A
or vehicle treatment. D, DMSO; W, WNT3A; V,
vehicle. Asterisk, n = 3, p < 0.05. Error bars, SD.
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glucose consumption (Figures 3C and 3D). Thus,WNT3A acutely
increases the protein levels of a number of key glycolytic regula-
tors to stimulate glycolysis.
We next investigated the signal transduction mechanism
through which WNT3A induces glycolysis. Because WNT3A
inhibits GSK3b activity, we first investigated the potential impor-
tance of GSK3b inhibition. Inhibition of GSK3b activity by either
genetic knockdown or LiCl did not increase glucose consump-
tion by itself, nor did it affect WNT3A-induced glucose consump-
tion (Figure 3E and data not shown), even though it increased
b-catenin levels as expected (Figure 3F, and data not shown).
Similarly, knockdown of b-catenin did not alter WNT3A-induced
glucose consumption, although it suppressed the induction of
IRS1, known to be induced transcriptionally by b-catenin (Yoon
et al., 2010) (Figures 3G and 3H). Knockdown of b-catenin with
a second shRNA also did not suppressWNT3A-induced glucose
consumption (Figure S3A). Finally, stabilization of AXIN1/2 with
the tankyrase inhibitor XAV939 inhibited b-catenin stabilization
by WNT3A but did not impair the induction of glucose consump-
tion (Huang et al., 2009) (Figures 3I and 3J). Thus, regulation of
AXIN, GSK3, or b-catenin is not the principle mechanism for
WNT3A to induce glycolysis.
WNT-LRP5 Signaling Activates mTORC2 via RAC1 to
Induce Glycolysis
We next investigated the potential role of mTOR signaling in
WNT-induced glycolysis. WNT3A acutely activated mTORC1,
as indicated by increased phosphorylation of the ribosomal pro-
tein S6, which was evident at 1 hr of stimulation and maintained748 Cell Metabolism 17, 745–755, May 7, 2013 ª2013 Elsevier Inc.after 24 hr (Figure 4A). In addition,WNT3A
activated mTORC2, as Ser473-phos-
phorylation of AKT was elevated at thesetime points (Figure 4A). Quantification of western blots frommul-
tiple independent experiments confirmed these findings (Figures
S2A–S2C). We further explored the temporal regulation of
mTOR signaling under serum-starved conditions. We found
that WNT3A activated both mTOR complexes in serum-starved
ST2 cells within 5 min of stimulation and throughout 24 hr of
treatment (Figures 4B and 4C). In contrast, WNT5A, which did
not induce glycolysis, did not stimulate mTORC2 (Figure S1J).
Confirming the activation of mTORC2 signaling by WNT3A,
phosphorylation of PKCa at S657, FOXO3A at T32, and
NDRG1 at T346, all previously shown to require mTORC2 activity
(Garcı´a-Martı´nez and Alessi, 2008; Guertin et al., 2006), were
also induced (Figures 4B and 4D). Furthermore, as in ST2 cells,
WNT3A activated mTORC2 and induced the glycolytic enzymes
in MEFs and primary osteoblast-lineage cells from the mouse
calvaria (Figure 4E). Knockdown of RICTOR, an mTORC2-
specific component, greatly reduced both basal and induced
mTORC2 signaling, but notmTORC1 (Figure 5A and Figure S4A).
RICTOR knockdown also abolished the upregulation of HK2 and
LDHA byWNT3A, as well asWNT3A-induced glucose consump-
tion, lactate production, and media acidification (Figures 5B–5D
and Figure S4B). The effects of RICTOR knockdown onWNT3A-
induced mTOR signaling, glycolytic enzymes, and glucose
consumption were all confirmed with a second shRNA (Figures
S4C–S4E). Similarly, PP242 and Torin 1, inhibitors of both
mTORC1 and mTORC2, greatly suppressed WNT3A-induced
glucose consumption (Figures S4F and S4G). MK-2206, an
allosteric AKT inhibitor preventing S473 phosphorylation,
completely abolished WNT3A-induced glucose consumption
as well as LDHA and PDK1 upregulation (Figures 5E and 5F).
Figure 4. WNT3A Activates mTORC2
(A–D) Representative western blots of mTOR tar-
gets in ST2 cells treatedwithWNT3A (W) or vehicle
(V) with (A) or without serum (B–D) for indicated
time. Cells in (B)–(D) were serum starved for 24
(B) or 12 (C and D) hr before treatment. ‘‘0 min’’
samples in (B) were treated with vehicle for 30min.
Phosphoprotein was normalized to respective
total protein, except for P-NDRG1 and P-S6K1 in
(C), which were normalized to b-actin.
(E) Effect of WNT3A on mouse calvarial cells or
MEFs. Calvarial cells treated with WNT3A or
vehicle for 1 hr after 12 hr serum starvation. MEFs
treated with WNT3A or vehicle for 6 hr in the
presence of serum.
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WNT3A-induced glucose consumption to a lesser degree, but
an even lower concentration (0.01 mM) did not have an effect
(Figure S4H). MK-2206 at the effective dosages did not affect
cell numbers (Figure S4I). In contrast to RICTOR, knockdown
of RAPTOR, an mTORC1-specific component, suppressed
mTORC1, but not mTORC2 activation or the induction of
PDK1, LDHA, and HK2 by WNT3A (Figures 5G and 5H and Fig-
ure S4J). Interestingly, RAPTOR knockdown activated basal
mTORC2 and increased the basal levels of the glycolytic
enzymes without WNT stimulation (Figures 5G and 5H), which
was likely responsible for the increased basal glucose consump-
tion (Figure 5I). Nonetheless, RAPTOR knockdown did not
prevent further stimulation of glucose consumption or lactate
production byWNT3A (Figures 5I and 5J). Conversely, activation
of mTORC1 by knockdown of TSC2 did not increase glucose
consumption by itself, nor did it affect WNT3A-induced glucose
consumption (Figure 5K, data not shown). Thus, WNT3A stimu-
lates glycolysis predominantly through mTORC2 activation.
HowdoesWNTsignalingactivatemTORC2?DKK1,whichpre-
ventsWNT from binding to LRP5 or LRP6, abolished LRP6 phos-
phorylation, mTORC2, but not mTORC1 activation by WNT3A at
1 hr (Figure 6A). Moreover, DKK1 abrogated the induction of
b-catenin, HK2, LDHA, GLUT1, and PDK1 after 24 hr of WNT3A
treatment (Figure 6B). Importantly, DKK1 abolished the increase
in glucose consumption in response to WNT3A (Figure 6C). To
distinguish the relative contribution of LRP5 versus LRP6 in this
regulation, we performed knockdown experiments. Remarkably,
knockdown of LRP5 alone essentially recapitulated the effect of
eitherDKK1, or double knockdownof LRP5andLRP6, in abolish-
ingWNT3A-induced glucose consumption, whereas knockdown
of LRP6 had a relatively minor effect (Figures 6D and 6E). The dif-
ferential effect of LRP5 versus LRP6 knockdown was confirmed
with a second shRNA for each molecule (Figures S3A and S3B).Cell Metabolism 17, 745We further examined potential compen-
sation between LRP5 and LRP6 when
eithermoleculewas knocked down. Inter-
estingly, LRP6 knockdown doubled Lrp5
mRNA but did not increase its protein
level, whereas LRP5 knockdown did not
affect either mRNA or protein of LRP6
(data not shown). Confirming the impor-
tance of mTORC2, knockdown of LRP5but not LRP6 suppressed mTORC2 activation, even though
either knockdown similarly suppressed the accumulation of the
stabilized form of b-catenin in response to WNT3A (Figure 6F).
Moreover, knockdown of LRP5 but not LRP6 eliminated the
induction of HK2 by WNT3A (Figure 6F). Thus, LRP5 appears to
be the principle mediator for WNT3A to stimulate glycolysis.
We next investigated how WNT-LRP5 signaling activates
mTORC2. Because we have previously shown that WNT-
LRP5/6 signaling activates the Rho family small GTPase RAC1
(Wu et al., 2008), and others have reported that RAC1 mediates
both mTORC1 and mTORC2 activation (Saci et al., 2011), we
examined the relevance of RAC1 in WNT3A-induced mTORC2
signaling. Knockdown of RAC1 suppressed the induction of
P-AKT, P-FOXO3A, and LDHA by WNT3A (Figure 6G and Fig-
ure S5A), as well as WNT3A-induced glucose consumption (Fig-
ure 6H). A second shRNA against RAC1 confirmed its role in
mTORC2 activation and glycolysis stimulation by WNT3A (Fig-
ures S5B–S5D). Because the previous study demonstrated
that RAC1 membrane translocation, but not its GFP-bound
form, mediates mTOR activation (Saci et al., 2011), we examined
the effect of WNT on RAC1 subcellular localization by confocal
microscopy. Indeed, WNT3A induced accumulation of RAC1 at
the plasma membrane (Figure 6I). Specifically, out of 85 cells
counted, 23 in the control but 61 in the WNT3A-treated sample
showed membrane localization of RAC1. Similarly, virally ex-
pressed WNT10B also induced RAC1 accumulation at the
plasma membrane (Figure S5E). Thus, WNT activates mTORC2
through LRP5 and RAC1 to stimulate glycolysis.
Metabolic Regulation Contributes to WNT-Induced
Osteoblast Differentiation
We then tested whether the metabolic regulation plays a role in
WNT-induced osteoblast differentiation in ST2 cells. Because
WNT induced glucose consumption, we hypothesized that–755, May 7, 2013 ª2013 Elsevier Inc. 749
Figure 5. WNT3A Induces Glucose Con-
sumption via mTORC2 Activation
(A–D) Effect of RICTOR knockdown (shRictor) on
mTORC1 versus mTORC2 (A), glycolytic enzymes
(B), glucose consumption (C), and lactate pro-
duction (D) after 24 hr of WNT3A (W) or vehicle (V)
treatment.
(E and F) Effect of AKT inhibitor MK2206 on
glycolytic enzymes (E) and glucose consumption
(F) after 24 hr of WNT3A (W) or vehicle (V)
treatment.
(G–J) Effect of RAPTOR knockdown (ShRptr) on
mTORC1 versus mTORC2 (G), glycolytic enzymes
(H), glucose consumption (I), and lactate produc-
tion (J) after 24 hr of WNT3A (W) or vehicle (V)
treatment.
(K) Effect of TSC2 knockdown (shTSC2) on
mTORC1 and glucose consumption after 24 hr of
treatment. shGFP or shLacz as negative control.
Asterisk, n = 3, p < 0.05. Error bars, SD.
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Indeed, reducing glucose concentration from the normal 5 mM
to 1 mM greatly impaired osteoblast differentiation in response
to WNT3A, as indicated by the decreased expression of Alpl
and Ibsp (Figure 7A), even though b-catenin was similarly stabi-
lized by WNT3A under both conditions (Figure 7B). The lower
glucose concentration did not affect cell numbers but markedly
reduced the extent of induction in glucose consumption by
WNT3A (Figure 7C and Figure S6A). The cells also produced
much less lactate with or without WNT3A (Figure S6B). The inhib-
itory effect of low glucose was specific to WNT3A, as BMP2
induced osteoblast differentiation similarly with either 5 mM or
1 mM glucose (Figure S6C). Next, we tested the role of mTORC2
in WNT3A-induced osteoblast differentiation. RICTOR knock-
down suppressed osteoblast differentiation (Figure 7D). Similarly,
Torin 1,which inhibits bothmTORC1andmTORC2, greatly dimin-
ished the expression of Alpl and Ibsp in response to WNT3A (Fig-
ure S6D). Finally, we examined the roles of glycolytic enzymes.
Knockdown of either LDHA or PDK1, both normally induced by
WNT3A, greatly reduced the induction of osteoblast marker
genes Col1a1 and Ibsp by WNT3A (Figure 7E). In addition, either
knockdown suppressed the level of Alpl expression in response
to WNT3A, whereas PDK1 knockdown also reduced the basal
level (Figure S6E). In contrast, neither knockdown impaired oste-
oblast differentiation in response to BMP2 (Figure S6F and data
not shown). Thus, reprogramming of glucose metabolism specif-
ically contributes to WNT-induced osteoblast differentiation.
WNT-LRP5 Signaling Increases Glycolysis In Vivo
Lastly, we tested whether WNT-LRP5 signaling reprograms
glucose metabolism in vivo. We first examined the Lrp5/750 Cell Metabolism 17, 745–755, May 7, 2013 ª2013 Elsevier Inc.mice that are known to be defective in
bone formation (Holmen et al., 2004;
Kato et al., 2002). These mutants at
6 weeks of age contained a much lower
level of HK2, LDHA, and PDK1 in their
bones when compared to the littermate
controls (Figure 7F). Moreover, the serumlactate levels in 1-month-old Lrp5/ mice were significantly
lower than those in their littermate controls (Figure 7G). To rule
out the possibility that the metabolic changes in bone were sec-
ondary to the effects on other tissues, we generated Osx-
Cre;Lrp5f/f mice (CKO) containing bone-specific deletion of
Lrp5. We found a notable decrease in the levels of HK2, PDK1,
and LDHA in the bones of CKOmice at 10 weeks of age, coupled
with reduced mTORC2 activity (Figure 7H). Analyses with mCT
techniques revealed obvious osteopenia in the CKO mice
when compared to the littermate control (Figure 7I and Figures
S7A and S7B). Consistent with reduced bone formation, the
serum P1NP (procollagen type I N-terminal propeptide) level
was lower in the CKO mice than in the control (Figure 7J). To
further establish the link between LRP5 andmetabolic regulation
in bone, we studied the high-bone-mass (HBM) mice harboring
the point mutation of A214V in LRP5 (Cui et al., 2011). We
confirmed by mCT analyses that mice either heterozygous or
homozygous for the mutant allele exhibited markedly higher
bone mass at 2 months of age (data not shown). Importantly,
bones from the HBM mice expressed higher levels of HK2,
PDK1, and LDHA (Figure 7K). The bonemarrow stromal cells iso-
lated from the HBM mice consumed more glucose than their
control counterparts when cultured in vitro, and the increase in
glucose consumption was suppressed by the mTOR inhibitor
Torin 1 (Figures 7L and 7M). Thus, LRP5 signaling modulates
glucose metabolism in bone cells in the mouse.
DISCUSSION
We have provided evidence that WNT signaling directly regu-
lates glucose metabolism independent of b-catenin signaling.
Figure 6. WNT3A Stimulates Glucose Consumption via LRP5 and RAC1
(A and B) Effects of DKK1 on WNT3A-induced phosphorylation and glycolytic enzymes. P-LRP6, P-AKT, and P-S6 normalized to respective total protein. Other
proteins normalized to b-actin.
(C) Effect of DKK1 on WNT3A-induced glucose consumption.
(D–F) Effect of LRP5 or LRP6 knockdown (D) on WNT3A-induced glucose consumption (E), and on signaling events after 1 hr of treatment (F). b-CAT* denotes
b-catenin unphosphorylated at N terminus.
(G) Effect of RAC1 knockdown on mTORC2 and LDHA induction by 24 hr WNT3A treatment.
(H) Effect of RAC1 knockdown on WNT3A-induced glucose consumption.
(I) Representative confocal images of RAC1 immunofluorescence. ST2 cells were serum starved overnight before being treated for 2 hr with vehicle (Ctrl) or
Wnt3a. Arrows denote RAC1 membrane localization. All glucose consumption was measured after 24 hr of WNT3A or vehicle treatment. V, vehicle; W, WNT3A.
Asterisk, n = 3, p < 0.05. Error bars, SD.
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WNT-LRP5-mTORC2 Signaling Induces GlycolysisSpecifically, WNT3A signals through LRP5 and RAC1 to activate
mTORC2 and AKT, resulting in upregulation of key glycolytic
enzymes. Functionally, the metabolic regulation contributes to
WNT-induced osteoblast differentiation in vitro and correlates
with the bone-forming activity of LRP5 signaling in vivo. This
study not only uncovers a mechanism through which WNT
signaling regulates cellular metabolism but also demonstrates
that metabolic regulation contributes to WNT-induced cell
differentiation.
The present study further expands the repertoire of signaling
cascades activated byWNT3A. In addition to b-catenin stabiliza-
tion, we have previously shown that WNT3A signals through
heterotrimeric G proteins to activate both PLCb-PKCd and
PI3K-RAC1 signaling in ST2 cells (Tu et al., 2007; Wu et al.,
2008). Here we show that WNT3A activates mTORC2 down-
stream of RAC1. Activation of the different pathways by
WNT3A may require distinct cell-surface receptor complexes,
as b-catenin stabilization and RAC1 activation are inhibited by
DKK1, but PKCd activation is not. Taken together, these studies
support the notion that WNT proteins activate multiple intracel-
lular signaling cascades highly dependent on the cellular
context, and do not possess intrinsic ‘‘canonical’’ or ‘‘noncanon-
ical’’ signaling properties (van Amerongen et al., 2008).
The mechanism through which mTORC2 induces glycolytic
enzymes remains to be further elucidated. The fact that theCinduction occurs abruptly following WNT3A treatment with no
change in mRNA levels indicates a transcription-independent
mechanism at work. We show that AKT, a direct target of
mTORC2, is critical for the induction of glycolytic enzymes and
glycolysis in response to WNT3A. Future studies are necessary
to determine whether and how mTORC2-AKT signaling affects
protein stability or translation of the glycolytic enzymes.
Our data identify LRP5 as a major coreceptor for WNT3A to
induce glycolysis. Although RNA-seq experiments revealed
that ST2 cells expressed three times as much Lrp6 mRNA as
Lrp5 (data not shown), knockdown of LRP6 did not have a major
effect on WNT3A-induced glucose consumption. In light of the
finding that LRP6 has a more potent function in mediating
b-catenin signaling (MacDonald et al., 2011), the two homolo-
gous coreceptors may have evolved to preferentially execute
different WNT signaling cascades. However, because we have
analyzed glucose metabolism only within the first 24 hr of
WNT3A treatment, LRP6 may regulate cell metabolism at later
time points through b-catenin signaling. Indeed, we found that
both Ldha and Pdk1 mRNA were induced by WNT3A at 24 hr
(Figure S2F), and that knockdown of b-catenin partially sup-
pressed the induction of LDHA and PDK1 proteins at this time
point (data not shown). Furthermore, induction of IRS1 by
b-catenin signaling may contribute to glucose metabolism in
response to insulin (Yoon et al., 2010) (this study). Thus, WNTell Metabolism 17, 745–755, May 7, 2013 ª2013 Elsevier Inc. 751
Figure 7. Metabolic Reprogramming by
WNT-LRP5 Signaling in Osteoblast Lineage
(A) Effect of glucose concentration on WNT3A-
induced osteoblast differentiation in ST2 cells after
4 days of stimulation. Expression of osteoblast
markers was determined by qPCR. Fold changes
between WNT3A- and vehicle-treated cells were
calculated after normalization to 18S RNA.
(B and C) Effect of glucose concentration on
b-catenin stabilization (B) and WNT3A-induced
glucose consumption (C) after 24 hr of treatment.
(D and E) Effect of RICTOR (D), LDHA, or PDK1
(E) knockdown on WNT3A-induced osteoblast
differentiation in ST2 cells after 4 days of treat-
ment. Expression of osteoblast markers was
determined by qPCR. Fold changes between
WNT3A- and vehicle-treated cells were calculated
after normalization to 18S RNA.
(F) Western blots of glycolytic enzymes in bone
protein extracts from Lrp5/ versus wild-type
littermates. > denotes correct band for HK2.
(G) Serum lactate levels from Lrp5/ versus wild-
type littermates.
(H) Western blots with bone protein extracts from
Lrp5CKO versus Osx-Cre littermates (Ctrl).
(I and J) Bone phenotype analyses of Lrp5CKO versus Osx-Cre littermates (Ctrl) by mCT (I) and serum P1NP assays (J).
(K) Western blots of glycolytic enzymes in bone protein extracts from homozygous LRP5 HBM mice versus wild-type littermates.
(L) Glucose consumption after 48 hr of culture by BMSC from LRP5 HBM (heterozygous or homozygous) mice versus wild-type littermates.
(M) Effect of Torin1 on 48 hr glucose consumption by BMSC from homozygous LRP5 HBM mice. D, DMSO. Asterisk, nR 3, p < 0.05. Error bars, SD.
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WNT-LRP5-mTORC2 Signaling Induces Glycolysissignaling may control glucose metabolism both through the
fast-acting, b-catenin-independent mechanism described here
and other slow-acting, b-catenin-dependent mechanisms,
which may be preferentially mediated by LRP5 and LRP6,
respectively. This conclusion is in agreement with the previous
reports that implicated LRP5, LRP6, and b-catenin in the regula-
tion of whole-body metabolism (Fujino et al., 2003; Liu et al.,
2011; Mani et al., 2007).
The finding that LRP5 mediates WNT-induced metabolic
reprogramming may have important implications for under-
standing the pathogenesis of bone disorders caused by LRP5
mutations. Although the role of LRP5 in regulating both osteo-
blast number and function in postnatal mice is well established,
the mechanism underlying LRP5 function has been a matter of
debate (Cui et al., 2011; Yadav et al., 2008). We have recently re-
ported that b-catenin is necessary for normal osteoblast life span
and activity in postnatal mice, lending support to the notion that
b-catenin may mediate some aspects of LRP5 signaling in post-
natal bones (Chen and Long, 2012). The current study provides
an additional mechanism through which LRP5 may regulate
osteoblast differentiation and function independent of b-catenin.
Future studies are necessary to determine the relative contribu-
tions of the different mechanisms to LRP5 function in vivo.
Beyond cells of the osteoblast lineage, WNT signaling may be
a general paracrine mechanism that modulates cellular meta-
bolism in the body. Besides cell differentiation, changes in
cellular metabolism are likely to influence other aspects of cell
physiology, as well as whole-body metabolism. Furthermore,
because insulin is an endocrine signal that controls glucose
metabolism, we expect that WNT may intersect with insulin
signaling to coordinate cellular metabolism. Indeed, a recent
report has shown physical interaction between LRP5 and insulin
receptor and interdependence between WNT and insulin752 Cell Metabolism 17, 745–755, May 7, 2013 ª2013 Elsevier Inc.signaling (Palsgaard et al., 2012). We observed greater potency
for WNT3A than insulin in inducing glucose consumption in ST2
cells, and that WNT3A exerted a similar effect in the absence of
serum (hence no insulin). Thus,WNT can operate independent of
insulin signaling in our setting. Future studies are necessary to
elucidate the interaction between WNT and insulin signaling in
regulating glucose metabolism.
‘‘Warburg effect’’ originally describes the phenomenon
whereby cancer cells often utilize glucose through glycolysis
over oxidative phosphorylation despite the abundance of
oxygen (Warburg, 1956). The phenomenon is now known to be
common to proliferating cells in culture. The reason for Warburg
effect continues to be an area of active research, but it has been
proposed that glycolysis produces the necessary intermediate
metabolites for fueling cell proliferation (Vander Heiden et al.,
2009). In our experiments, WNT induced cell differentiation
without an obvious effect on proliferation. How increased glycol-
ysis promotes differentiation remains to be investigated in the
future, but it may alter the levels of key intermediate metabolites
that regulate gene expression. Overall, our study has identified
metabolic regulation as a new mechanism for WNT proteins to
induce cell differentiation.
EXPERIMENTAL PROCEDURES
Mouse Strains
Osx-Cre, Lrp5f/f, Lrp5/, Lrp5HBMmice are as previously described (Cui et al.,
2011; Holmen et al., 2004; Joeng et al., 2011; Rodda and McMahon, 2006).
The Animal Studies Committee at Washington University has reviewed and
approved all mouse procedures used in this study.
Antibodies
Antibodies for p-Lrp6 (cat#2568), p-Akt(S473) (cat#9271), Akt (cat#9272),
p-S6 (cat#2215), S6 (cat#2217), Raptor (cat#2280), Rictor (cat#2140),
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WNT-LRP5-mTORC2 Signaling Induces GlycolysisLrp5 (cat#5731), b-actin (cat#4970), FoxO3a (cat#2497S), p-FoxO3a-T32
(cat#9464S), p-NDRG1-Thr346 (cat#3217S), and P-S6K (cat#9205) are
from Cell Signaling Technologies. Hk2 (sc-6521), Ldha (sc-27230), Pfk1
(sc-31712), Lrp6 (sc-25317), a-tubulin (sc-8035), and p-PKCa-Ser 657
(sc-12356) total PKCa (sc-208) antibodies are from Santa Cruz Biotechnology.
Pfkfp3 (ab96699) antibody is from Abcam. Antibody for unphosphorylated
b-catenin (05-665) is fromMillipore. Pdk1 (KAP-pk112) antibody is from Assay
Designs. RAC1 antibody (610650) is from BD Biosciences. Glut1 polyclonal
antibody F350 is as previously described and was kindly provided by Dr.
Michael Mueckler (Washington University School of Medicine) (Haney et al.,
1991). HRP-conjugated anti-rabbit secondary antibody is from GE Healthcare
(NA934V), and HRP-conjugated anti-mouse (sc-2005) and anti-goat (sc-2352)
secondary antibodies are from Santa Cruz Biotechnology.
Western Blot
Protein extracts from cells or bone were prepared in RIPA buffer containing
phosphatase and proteinase inhibitors. Membranes were imaged with Molec-
ular Imager ChemiDoc XRS+ System (Bio-Rad). Quantification of western
blots was performedwith ImageLab software or PhotoshopCS3. Detailed pro-
cedure is provided in the Supplemental Experimental Procedures.
Quantitative PCR
RNA was isolated from whole cells with QIAGEN RNeasy kit (#74104) and was
transcribed into cDNA using iScript cDNA synthesis kit (Bio-Rad). Fast-start
SYBR Green (Bio-rad) and 0.05 mM primers were used in each reaction. 18S
RNA was used for normalization. The primer sequences and additional infor-
mation are provided in the Supplemental Experimental Procedures.
Cell Culture
For routine cultures, ST2 cells were grown in a-MEM (GIBCO, cat#12561),
MC3T3 subclone 4 cells were grown in a-MEM (GIBCO catalog number
A1049001), HEK293T and 3T3-L1 cells were grown in DMEM (GIBCO catalog
number 11965), and M2-10B4 cells (ATCC CRL-1972) were grown in RPMI
(GIBCO, catalog number 11875), all supplemented with 10% heat-inactivated
FBS (GIBCO) and Pen Strep (GIBCO, catalog number 14140). MLO-Y4 cells
were grown on pre-collagen-coated plates in a-MEM containing nucleosides
(GIBCO, catalog number 12571-063) supplemented with heat-inactivated
FBS (2.5%), calf serum (2.5%), and Pen Strep.
For all experiments, unless indicated otherwise, cells were cultured in
glucose- and glutamine-free a-MEM (GIBCO, custom made from catalog
number 12561) containing 10% FBS and Pen Strep, and freshly supplemented
with 5.5 mM glucose plus 2 mM glutamine. Recombinant mouse Wnt3a (R&D
Systems) was used at 50 ng/ml unless indicated otherwise. As a vehicle con-
trol for Wnt3a, PBS with 0.5% CHAPS and 0.1 mM EDTA was used. Recom-
binant human BMP2 (R&D Systems) was used at 300 ng/ml. Recombinant
mouse Dkk1 (R&D Systems) was used at 500 ng/ml, and cells were pretreated
with Dkk1 for 30 min before the addition of Wnt3a. Torin1 (Tocris Biosciences),
PP242 (Sigma), and rapamycin (Sigma), all dissolved in DMSO, were used at
20, 10, and 100 nM, respectively. Insulin (Sigma) was used at 1 or 2 mg/ml.
Bonemarrow stromal cells (BMSCs), calvarial cells, andMEFs were isolated
from mouse adult long bones, newborn calvaria, and E13.5 embryos, respec-
tively, according to established protocols. Detailed methods are provided in
the Supplemental Experimental Procedures.
Glucose Consumption and Uptake Assays, Lactate and ATP
Measurements
For glucose consumption measurements, aliquots of the media and glucose
standards were assayed with Glucose (HK) Assay Kit (Sigma catalog number
GAHK20) and read at 340 OD using a plate reader (BioTek model SAMLFTA,
Gen5 software). For glucose uptake assays, cells were incubated with 100 mM
2-NBDG for 30 min and then prepared for fluorescence reading following the
manufacturer’s instructions (Glucose Uptake Cell-Based Assay Kit, Cayman
Chemical). Fluorescence intensitymeasuredat485/535nm(excitation/emission)
using a plate reader (BioTek model SAMLFTA, Gen5 software) was normalized
to the protein content in each well. For lactate measurements, L-lactate assay
kit from Eton biosciences (catalog number 1200011002) was used. To measure
lactate levels in the serum,mice were fasted for 8 hr before blood was collected
from the periorbital venous sinus under anesthesia. Intracellular ATP wasCmeasured based on a method previously described (Chi et al., 2002). Additional
information is provided in the Supplemental Experimental Procedures.
OCR and ECAR Measurements with Seahorse Cellular Flux Assays
ST2 cells were plated in XF96 plates at 20,000 cells per well after coating the
plates with cell-tak (BD Biosciences). The next day, the cells were treated with
100 ng/ml Wnt3a for 6 hr, then switched to XF Assay Medium Modified DMEM
(Seahorse cat#101022-100) supplemented with 5.5 mM glucose, and further
incubated in CO2-free incubator for 1 hr. Oligomycin and FCCP (Seahorse
Stress Kit) were prepared in XF assay medium with final concentration of
5 mM and 1 mM, respectively, and were injected during the measurements. At
the end of the assays, protein concentrations were measured for normalization.
shRNA Knockdown and Retroviral Infection
Lentiviral shRNA targeting vectors were purchased from Genome Center at
Washington University. Targeted sequences and virus production procedure
are provided in the Supplemental Experimental Procedures. Retroviruses
expressing WNT10B or GFP were generated according to a procedure as pre-
viously described (Hu et al., 2005).
Analyses of Postnatal Mouse Bones
Micro-CT analyses were performed with Scanco mCT 40 (Scanco Medical AG)
according to ASBMR guidelines (Bouxsein et al., 2010). Quantification of the
trabecular bone in the proximal tibia was performed with 100 mCT slices
(1.6 mm total) immediately below the growth plate. To measure P1NP in the
serum, serum was collected from mice after 6 hr of fasting and analyzed
with Rat/Mouse P1NP EIA kit (Immunodiagnostic Systems, Ltd., catalog
number DS-AC33F1).
Bone protein extracts were prepared from femurs and tibias of postnatal
mice with RIPA buffer.
After removal of both epiphyses of each bone, bone marrow cells were
removed by brief centrifugation. The remaining bone shafts were rinsed twice
in the cold PBS, flash frozen in liquid nitrogen, and thenmanually ground into a
fine power with a mortar/pestle. The bone power was incubated on ice for
30 min, with 200 ml RIPA buffer containing phosphatase inhibitors (Roche,
catalog number 04906845001) and proteinase inhibitors (Roche, catalog
number 11 836 170 001). The protein extracts were then collected after centri-
fugation for 10 min.
GC/MS Analyses
At the end of theWnt3a treatment, [U-13C6] glucose was added to the medium
at a final concentration of 0.55 mM and incubated for 1 hr. At the end of the
[U-13C6] incubation, an aliquot of medium from each sample was collected
for analyses. The cells were then washed with cold PBS and extracted three
times with 80 C methanol on dry ice. Extracts were dried in a centrifugal
concentrator (Savant SpeedVac, Thermo Scientific, Millford, MA) and derivat-
ized at 70C for 30 min with either 1:1 acetonitrile:N-methyl-N(tert-butyldime-
thylsilyl)trifluoroacetamide (MTBSTFA, to make tert-butyldimethylsilyl deriva-
tives [tBDMS] of lactate) or 10% heptafluorobutyric anhydride in ethyl
acetate (to make heptafluorobutyryl derivative [HFB] of glucose).
GC-MS/EI analyses were performed with Hewlett-Packard 6890 series gas
chromatograph interfaced to an Agilent 5973N mass spectrometer. Helium
was the carrier gas at constant flow rate of 1.0 mL/min. The injector and the
transfer line temperatures were set at 250C and 280C, respectively. GC anal-
ysis was performed with a DB-5MS column (30 m 3 0.25 mm 3 0.25 mm;
Agilent). The initial temp of the oven was 90C held for 0 min and then ramped
at 20C per min to 230C, and next ramped at 70C per min to 275C held for
3.5 min for a total run of 11 min. Sample (2.0 ml) in heptane was injected with a
7683 autosampler (split mode; split ratio of 5:1). The electron energy was set at
70 eV and the ion source temperature kept at 230C.
Isotopomer distributions were measured by electron impact ionization for
tBDMS derivative of lactate (m/z 261–264) and for the HFB derivative of
glucose (m/z 519–525). All isotopomer distributions were corrected for natural
abundance and for spectral overlap (Wolfe and Chinkes, 2004).
Statistical Analyses
All quantitative data are presented as mean ± STDEV with a minimum of three
independent samples. Statistical significance is determined by Student’s t test.ell Metabolism 17, 745–755, May 7, 2013 ª2013 Elsevier Inc. 753
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